BA

BioM AG

Description

BioM supports biotech companies with funding, networking, and services, fostering innovation and growth in the life sciences sector.

Investor Profile

BioM AG has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (67%)
  • Series A (33%)

Country Focus

  • Germany (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Biopharma
  • Therapeutics
  • Medical
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does BioM AG frequently co-invest with?

Gilde IT Fund
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
3i Group
Europe, England, United Kingdom, London
Co-Investments: 1
BayTech Venture Capital
Europe, Bayern, Germany, München
Co-Investments: 1
Forbion Capital Partners
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 1
MC
Europe, Bayern, Germany, München
Co-Investments: 1
AAC Capital Partners
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
Bayern Kapital
Europe, Bayern, Germany, Landshut
Co-Investments: 1
Global Life Science Ventures
Europe, Bayern, Germany, München
Co-Investments: 1
Deutsche Venture Capital
Europe, Bayern, Germany, München
Co-Investments: 1

What are some of recent deals done by BioM AG?

ConoGenetix biosciences

Martinsried, Bayern, Germany

ConoGenetix biosciences is a biotechnology company that focuses on the development of peptide-based drugs.

BiopharmaBiotechnologyHealth CareTherapeutics
Series AApr 23, 2012
Amount Raised: $1,971,373
Pieris AG

Hallbergmoos, Bayern, Germany

Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and so on.

BiotechnologyHealth CareMedicalPharmaceutical
Series BNov 1, 2006
Amount Raised: $6,390,000
4SC

Planegg, Bayern, Germany

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases.

BiopharmaBiotechnologyTherapeutics
Series BDec 12, 2000
Amount Raised: $15,030,853